Skip to main content Skip to page footer

Diagnosed with prostate cancer?

Rely on cutting-edge technology and 15 years of experience.

Many treatment methods can be considered for malignant prostate tumors, primarily surgery or radiotherapy.

 

Surgery and radiotherapy are equally effective methods, each with advantages and disadvantages in terms of potential side effects. At our centers, we will be happy to provide you with information about the risks and benefits of the various treatment options.

Radiotherapy for prostate cancer has historically lasted 6-8 weeks with a total of 30-40 treatment sessions (so-called normo- or moderate hypofractionation). In recent years, however, ultra-hypofractionated radiotherapy (radiosurgery) with approx. 3-5 treatment sessions has become increasingly popular. 

 

 

With our Saphir radiosurgery centers in Kiel and Frankfurt, we are among the key pioneers who validated radiosurgery for prostate cancer in Germany as part of clinical studies, the so-called HYPOSTAT studies.

 

Thanks to excellent results and over 15 years of expertise, we have made a decisive contribution to establishing and standardizing the treatment of prostate tumours using the CyberKnife system.  

When it comes to the treatment of prostate tumors, we are happy to be your contact.

What exactly is prostate cancer?

Prostate cancer is caused by altered genetic information in individual cells. The body recognizes and controls many of these genetically modified cells. However, if cells escape the body's control mechanism, they divide unchecked.

 

They then multiply faster than normal body cells and displace healthy body tissue. This is how a tumor develops.

A distinction is made between benign and malignant tumors. The latter include carcinomas - including prostate tumors.

 

Prostate cancer originates from the glands of the prostate. If it spreads, metastases can form in the lymph nodes, bones or other organs. We are therefore dealing with a malignant disease. 

Do I have prostate cancer?

Early stages of prostate cancer often cause no symptoms. Regular screening is therefore crucial as it can help to detect prostate cancer at an early, more treatable stage. However, if symptoms do occur, these may include the following:

 

  • Frequent or painful urination
  • Weak or interrupted urine flow
  • Blood in the urine or semen
  • Pain in the lower back, hips or pelvis
  • Erectile dysfunction
  • However, if in doubt, always ask your doctor.

Advantages of the CyberKnife treatment.

 

  • appointments without the need for follow-up rehabilitation
  • Precision: Irradiation of the tumor with millimetre precision despite strong prostate movements and thus maximum protection of the rectum and bladder
  • Speed: Significantly shorter treatment times (3-5 sessions) compared to conventional radiotherapy (30-40 sessions)
  • Low side effects: Proven low side effects compared to conventional radiotherapy or surgery (HYPOSTAT studies and PACE studies)
  • High effectiveness: Proven high effectiveness with organ and function preservation compared to conventional radiotherapy or surgery (HYPOSTAT studies and PACE studies)

Our experienced specialists and specialized teams will guide you through the entire treatment process and ensure that your therapy is tailored to your individual needs. From cost coverage to aftercare.

Appointment Kiel Appointment Frankfurt

20

years of clinical studies on the treatment of prostate cancer using CyberKnife.1

 

20,000

men (and more) have already been treated with the  CyberKnife worldwide.2

 

98%

of all patients would recommend CyberKnife treatment to other people.

 

[Translate to English:]

1 1 Meier. R. et al. “Five-Year Outcome From a Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer.” International Journal of Radiation Oncology • Biology • Physics, Volume 96, Issue 2, S33 – S34. - 2 Fuller D.B., et. al. “5-year outcomes from a prospective multi-institutional trial of heterogeneous dosing stereotactic body radiotherapy (SBRT) for low- and intermediate-risk prostate cancer.” J Clin Oncol 35. 2017; 6S;35.

 

2 https://cyberknife.com/prostate-cancer/

3 https://accuraystage.wpengine.com/patients/